1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Mezzion Pharma Co., Ltd.

Mezzion Pharma Co., Ltd.

KKRX:140410
57,600.00
KRW
+100.00
(+0.17%)
-1,223.61EPS
2.63TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
201.37
212.49
659.85
395.84
250.23
766.14
689.8
1,100.84
998.74
1,149.55
1,123.96
288.72
262.68
264.15
Basic EPS, GAAP
-38
-112.33
186.67
-587.33
-666.67
-757.67
-895
-531.67
-509.7
-1,358
-451
-653
-1,160
-1,223.61
Free Cash Flow per Basic Share
-162.99
-207.96
53.41
-282.53
-683.71
-894.93
-846
-589.48
-796.4
-517.63
-810.75
-1,071.81
-991.69
-1,023.39
Dividend per Share
8.34
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2,847.78
2,895.11
2,828.49
2,388.53
2,233.77
2,225.92
1,639.88
2,129.45
2,351.55
981.23
2,075.31
1,537.3
565.76
510.36
Tangible Book Value per Share
2,798.14
2,762.63
2,713.99
2,374.65
2,165.06
2,162.42
1,577.86
1,820.52
1,820.58
920.66
1,638.14
588.16
-1,050.37
-1,381.04
Basic Weighted Avg Shares
22
23
23
22
22
25
26
26
27
27
28
30
30
30
Sales/Revenue/Turnover
4,402
4,857
14,926
8,751
5,586
19,088
17,920
28,634
26,654
30,726
31,721
8,612
7,910
7,972
Operating Margin (%)
-56.17
-101.22
-18.31
-82.5
-301.59
-114.87
-136.62
-26.3
-63.02
-75.93
-45.68
-166.05
-212
-223.45
Depreciation Expense
48
151
343
415
62
228
1,332
1,432
1,586
1,658
1,546
958
988
920
Net Income, GAAP
-831
-2,568
4,223
-12,985
-14,882
-18,876
-23,251
-13,829
-13,603
-36,298
-12,728
-19,477
-34,929
-36,928
Effective Tax Rate (%)
- -
- -
18.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-18.87
-52.86
28.29
-148.38
-266.42
-98.89
-129.75
-48.3
-51.03
-118.13
-40.13
-226.17
-441.61
-463.23
Working Capital
58,103
62,804
83,609
77,713
50,007
52,278
38,339
45,155
45,678
19,817
44,628
15,255
-33,987
-43,953
LT Debt
- -
- -
25,236
26,255
- -
- -
2,420
3,104
2,338
1,625
1,005
921
1,151
1,032
Total Equity
62,177
66,151
62,537
52,809
53,169
57,319
42,830
56,810
62,793
26,240
61,444
46,063
17,195
15,511
Return on Invested Capital (%)
- -
- -
-2.91
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
7.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-1.32
-4
6.56
-22.51
-28.08
-34.17
-46.43
-27.76
-22.75
-81.54
-29.03
-36.23
-110.43
-125.67

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
9,996
10,722
11,388
LT Borrowings
- -
- -
- -
LT Finance Leases
930
1,151
1,032
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
1,964,426
2,738,334
2,631,962

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
43,508
45,586
38,313
Cash, Cash Equivalents & STI
28,493
25,574
17,419
Accounts Receivable, Net
1,104
1,078
939
Inventories
5,379
5,302
5,242
Total Current Liabilities
49,394
79,572
82,267
Payables & Accruals
- -
- -
- -
ST Debt
9,996
10,722
11,388
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.09%
-0.24%
-62.67%
Free Cash Flow
-35.6%
20.44%
-6.59%
Net Income, GAAP
-15.08%
46.53%
79.34%
Sales/Revenue/Turnover
14.85%
-13.88%
-8.15%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,158
2,269
2,261
1,924
8,612
2025
1,953
1,744
2,128
2,084
7,910
2026
2,015
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.45
-55
-213
-387.09
-653
2025
-110
-61.72
-171.05
-811.51
-1,160
2026
-174.66
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dong-Hyun Park
Full Time Employees
18
Sector
Health technology
Industry
Pharmaceuticals: major
Address
570 Samseong-ro, Seokcheon Building, 7th Floor Seoul SL South Korea 6163
IPO Date
Jan 20, 2012
Website
mezzion.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Mezzion Pharma Co., Ltd. develops, manufactures, and sells pharmaceutical products with a focus on treatments for rare and underserved diseases, including udenafil (JURVIGO) in phase 3 clinical trials for improving exercise capacity and physiology in Fontan patients aged 12 years and older; udenafil for erectile dysfunction (Zydena), benign prostatic hyperplasia, portal hypertension, pulmonary arterial hypertension, overactive bladder, and chronic obstructive pulmonary disease; and exploratory applications in autosomal dominant polycystic kidney disease. The company operates primarily in South Korea with global clinical development led by its U.S. subsidiary, Mezzion Pharmaceuticals, Inc., headquartered in Fort Lee, New Jersey, and targets patients with congenital heart conditions, vascular diseases, and renal disorders through licensing agreements with partners such as Warner in the U.S., Valenta in Russia, Nycomed in Mexico, and Dr. Falk in Europe. Founded in 2002 and headquartered in Seoul, South Korea, the company changed its name from Dong-A Pharmtech Co., Ltd. in April 2013. In June 2025, Mezzion secures approximately $20 million in strategic funding from Midas-Meritz New Technology Finance Association and KDBC-Korea Investment & Securities New Technology Investment Association to advance the global phase 3 FUEL-2 trial of udenafil for Fontan patients; expands its udenafil pipeline with a pre-clinical study for ADPKD in collaboration with Mayo Clinic; and benefits from new ICD-10 codes recognizing Fontan-associated conditions to support regulatory and coverage advancements.